Unlock efficient market access with Pure Global & MEDIcept's collaboration. From registration to regulatory expertise, we offer comprehensive solutions worldwide. Drive growth & innovation in MedTech.
Jersey City & Boston, 2 May 2024 – Pure Global, a leader in global market access services, and MEDIcept, renowned for its expertise in US and EU regulatory, quality, and clinical services, proudly announce their strategic collaboration. This alliance aims to revolutionize the medical device and in vitro diagnostics (IVD) industry by combining their strengths to unlock new opportunities and streamline market access worldwide.
Pure Global and MEDIcept recognize the paramount importance of regulatory compliance and market access for global success in the medical device and IVD sectors. By joining forces, the two entities aim to leverage their expertise and networks to navigate regulatory complexities efficiently. Pure Global brings to the table extensive experience in global representation and registration services alongside their cutting-edge AIGC regulatory tools. On the other hand, MEDIcept boasts a solid reputation in regulatory, quality, and clinical services for the US and EU markets. Together, they provide comprehensive solutions ranging from regulatory affairs and quality assurance to clinical support and market representation across regions like the US, Latin America, Europe, the Middle East, and Asia Pacific.
This alliance is of significant importance to the industry as it unites two companies with complementary strengths, enhancing their ability to navigate regulatory landscapes and facilitate market access effectively. By pooling their expertise, Pure Global and MEDIcept aim to drive growth and innovation, ultimately benefiting their clients and the industry as a whole.
Pure Global and MEDIcept are aligned in their pursuit of several objectives through this collaboration:
Both Pure Global and MEDIcept will continue their operations with an expanded service portfolio. The collaboration will see the companies leveraging their combined resources to enhance efficiency and deliver greater value to their clients.
The initial action following the alliance will involve a collaborative marketing effort to promote each other's services. By working together, Pure Global and MEDIcept aim to advance the medical device industry and remove barriers to innovation.
"Pure Global's strategic alliance with MEDIcept will help accelerate MedTech innovation and streamline compliance. By combining their hundreds of successful submissions since 1996 with our AI-powered & data driven regulatory solutions, we empower clients worldwide to bring life-changing MedTech to market faster, with reduced costs and higher regulatory success." said Zhu (Phyllis) Meng, CEO of Pure Global.
“With this strategic alliance we are strengthening our worldwide presence and can serve the needs of our customers anywhere. With teams of seasoned consultants both MEDIcept and Pure Global offer deep expertise across a wide range of compliance needs. Together, this relationship will efficiently help international companies with FDA and US quality, regulatory, clinical, and reimbursement concerns and rapidly provide tailored, trusted solutions to meet their unique challenges.” stated David Rothkopf, President of MEDIcept.
Contact us for a non-obligatory discussion today!
Browse our news hub featuring company announcements, regulatory updates, and industry insights to keep you informed and ahead of the curve.
Whether looking for more information or ready to partner with us, we're here to guide you through every step of the regulatory process.
Explore our collection of articles, success stories, and regulatory updates, designed to help you take your product global.
.png)
As 2024 comes to a close, Pure Global proudly reflects on a transformative year marked by substantial growth, cutting-edge innovation, and impactful collaborations.
IVD manufacturers cite the new classification system, detailed definitions for intended purposes, and the need for verification of clinical evidence as key challenges under the IVDR.
(3).png)
On October 23, the European Parliament adopted a resolution revising specific elements of the Medical Devices Regulation (MDR) and the In Vitro Diagnostic Devices Regulation (IVDR). This resolution intends to address ongoing challenges in implementing the regulations by 2025 and to improve patient access to important medical products.
Multilingual documentation presents ongoing compliance and logistical hurdles for MedTech manufacturers. Transla.Ai is an industry-specific translation tool that can accelerate and streamline the translation process.